MERCK KGAA
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 88
- Registration Number
- NCT01982955
- Locations
- 🇨🇳
Jilin University, Changchun, China
🇨🇳Jilin Cancer Hospital, Changchun, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, China
Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 200
- Registration Number
- NCT01977794
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center located in, Darmstadt, Germany
ATX-MS-1467 in Multiple Sclerosis
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 37
- Registration Number
- NCT01973491
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center, Darmstadt, Germany
Japanese Phase 1 Trial of Sym004 in Solid Tumors
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2017-08-23
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 51
- Registration Number
- NCT01955473
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center located in, Darmstadt, Germany
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 57
- Registration Number
- NCT01943461
- Locations
- 🇩🇪
Research site, Darmstadt, Germany
Study to Verify Clinical Utility of Point-of-Care (POC) Thyroid Stimulating Hormone (TSH) Test Kits as Compared to Third Generation TSH Test Kit
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-08-13
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 283
- Registration Number
- NCT01921452
- Locations
- 🇨🇳
Research site, Shanghai, China
Low-dose Gonal-f® in Ovulation Induction
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 24
- Registration Number
- NCT01871532
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
🇬🇧Research site, London, United Kingdom
Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 178
- Registration Number
- NCT01863680
- Locations
- 🇯🇵
Research site, Yokohama, Kanagawa, Japan
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 20
- Registration Number
- NCT01833546
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors
- First Posted Date
- 2013-04-16
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 12
- Registration Number
- NCT01832506
- Locations
- 🇯🇵
Research site, Shizuoka, Japan
© Copyright 2024. All Rights Reserved by MedPath